Context Therapeutics IncNASDAQ CNTX Stock Report

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. The company is headquartered in Philadelphia, Pennsylvania and currently employs 7 full-time employees. The company went IPO on 2021-10-20. The firm is focused on developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers. Its lead product candidate, onapristone extended release (ONA-XR), is a selective and potent antagonist of the progesterone receptor (PR), a receptor that is activated by the hormone progesterone and that has been linked to resistance to multiple classes of cancer therapeutics, including anti-estrogen therapies. Its ONA-XR consists of three Phase II clinical trials and one Phase 1Ib/II clinical trial in hormone-driven breast, ovarian, and endometrial cancer. Its second program, CLDN6xCD3 bsAb, is an anti-CD3 x anti-Claudin 6 (CLDN6) antigen bispecific monoclonal antibody (bsAbs) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.